BOOM

Trending Searches

    SUPPORT
    BOOM

    Trending News

      • Fact Check 
        • Fast Check
        • Politics
        • Business
        • Entertainment
        • Social
        • Sports
        • World
      • Law
      • Explainers
      • News 
        • All News
      • Decode 
        • Impact
        • Scamcheck
        • Life
        • Voices
      • Media Buddhi 
        • Digital Buddhi
        • Senior Citizens
        • Videos
      • Web Stories
      • BOOM Research
      • BOOM Labs
      • Deepfake Tracker
      • Videos 
        • Facts Neeti
      • Home-icon
        Home
      • About Us-icon
        About Us
      • Authors-icon
        Authors
      • Team-icon
        Team
      • Careers-icon
        Careers
      • Internship-icon
        Internship
      • Contact Us-icon
        Contact Us
      • Methodology-icon
        Methodology
      • Correction Policy-icon
        Correction Policy
      • Non-Partnership Policy-icon
        Non-Partnership Policy
      • Cookie Policy-icon
        Cookie Policy
      • Grievance Redressal-icon
        Grievance Redressal
      • Republishing Guidelines-icon
        Republishing Guidelines
      • Fact Check-icon
        Fact Check
        Fast Check
        Politics
        Business
        Entertainment
        Social
        Sports
        World
      • Law-icon
        Law
      • Explainers-icon
        Explainers
      • News-icon
        News
        All News
      • Decode-icon
        Decode
        Impact
        Scamcheck
        Life
        Voices
      • Media Buddhi-icon
        Media Buddhi
        Digital Buddhi
        Senior Citizens
        Videos
      • Web Stories-icon
        Web Stories
      • BOOM Research-icon
        BOOM Research
      • BOOM Labs-icon
        BOOM Labs
      • Deepfake Tracker-icon
        Deepfake Tracker
      • Videos-icon
        Videos
        Facts Neeti
      Trending Tags
      TRENDING
      • #Operation Sindoor
      • #Pahalgam Terror Attack
      • #Narendra Modi
      • #Rahul Gandhi
      • #Waqf Amendment Bill
      • #Arvind Kejriwal
      • #Deepfake
      • #Artificial Intelligence
      • Home
      • Coronavirus
      • COVID-19 Vaccine Shots For 12-14...
      Coronavirus

      COVID-19 Vaccine Shots For 12-14 Year Olds From March 16

      The children will receive Biological E's recombinant protein Corbevax vaccine which was produced by scientists at the Baylor College of Medicine in Houston.

      By - Shachi Sutaria |
      Published -  14 March 2022 4:34 PM IST
    • Boomlive
      COVID-19 Vaccine Shots For 12-14 Year Olds From March 16

      The Ministry of Health and Family Welfare has announced that children born in the years 2008, 2009, and 2010 will now receive their COVID-19 shots from March 16. Earlier this year, those above 14 years of age started receiving their COVID-19 shots.

      While the teenagers were administered Bharat Biotech's Covaxin, the new age group will be vaccinated with Hyderabad's Biological E's Corbevax. Biological E is producing this patent free vaccine in collaboration with scientists at the Baylor College of Medicine, Houston.

      The vaccine is produced differently than the vaccines currently in use across the world. All the vaccines either use adenoviral vectors, inactivated SARS-CoV-2 or mRNA platforms to grow the vaccine. Corbevax uses recombinant protein technology to produce the vaccine. Recombinant proteins are those where specific proteins are allowed to replicate without the help of an original replicating RNA or DNA and allowed to express their role on their own. In this case, the spike protein was produced without any infectious components of the existing virus.

      This Corbevax vaccine uses an already established technology platform to release the protein sub-unit. The SARS-CoV-2 protein is released by a yeast which is how Hepatitis B vaccines are created as well. While Hep B vaccines use the yeast Saccharomyces cerevisiae as the host and medium for recombination, the COVID-19 vaccine uses another yeast called Pichia pastoris wherein the spike protein will replicate.

      The scientists Peter Hotez and Maria Bottezi who developed the vaccine believe that this vaccine could act as perfect booster dose vaccine to curb the spread of the ongoing Omicron variant. To ensure equitable access to everybody, they have decided to not issue a patent on the production technology of the vaccine.

      Also Read:How Is Biological E's Corbevax Different From Other COVID Vaccines

      The Indian government has reportedly placed an order of 300 million doses. This vaccine will only be available for the specific age group of those between 12-14. It cannot be used as a booster/ precaution dose.

      The Ministry also shared that it is removing its earlier mandate for those above 60 who want to take a precautionary booster dose. Those above 60 were earlier required to present a certificate bearing a doctor's signature that showed that they suffered from pre-existing comorbidities. As this rule is now removed, every citizen in this age group can now go ahead and take the booster shot. They cannot mix vaccines and will have to take the same shot as their first two shots (Covishield, Covaxin, Sputnik).

      Also Read:India Approved Eight COVID-19 Vaccines, Only Three Are In Use



      Tags

      corbevaxCOVID-19
      Read Full Article
      Next Story
      Our website is made possible by displaying online advertisements to our visitors.
      Please consider supporting us by disabling your ad blocker. Please reload after ad blocker is disabled.
      X

      Subscribe to BOOM Newsletters

      👉 No spam, no paywall — but verified insights.

      Please enter a Email Address
      Subscribe for free!

      Stay Ahead of Misinformation!

      Please enter a Email Address
      Subscribe Now🛡️ 100% Privacy Protected | No Spam, Just Facts
      By subscribing, you agree with the Terms & conditions and Privacy Policy connected to the offer

      Thank you for subscribing!

      You’re now part of the BOOM community.

      Or, Subscribe to receive latest news via email
      Subscribed Successfully...
      Copy HTMLHTML is copied!
      There's no data to copy!